Silicon Biosystems Appoints Farideh Bischoff, Ph.D. as Executive Director of Scientific Affairs

Share Article

Silicon Biosystems, Inc. announced the appointment of Farideh Bischoff, Ph.D. as Executive Director of Scientific Affairs. Dr. Bischoff has more than 20 years of experience in reproductive genetics and cancer research and diagnostics.

Silicon Biosystems Logo

“Farideh brings an extraordinary depth of experience and working knowledge of the science in two key areas where our technology applies." -Robert Proulx

Silicon Biosystems, Inc. announced the appointment of Farideh Bischoff, Ph.D. as Executive Director of Scientific Affairs. Dr. Bischoff has more than 20 years of experience in reproductive genetics and cancer research and diagnostics. Prior to joining Silicon Biosystems, Dr. Bischoff served as Vice President of Translational Research and Clinical Development at Biocept, Inc. where she was responsible for overseeing clinical studies, assay development for commercialization and CLIA validation, and academic collaborations. At Silicon Biosystems she is expected to have responsibility for all scientific collaborations and helping to define and drive the clinical strategy for the company.

“We are extremely happy to have Dr. Bischoff join our company,” said Robert Proulx, President of Silicon Biosystems, Inc. “Farideh brings an extraordinary depth of experience and working knowledge of the science in two key areas where our technology applies. Her recent work in developing a CLIA certified test for metastatic breast cancer based on CTCs and the relationships she has within the cancer research and diagnostics community will directly impact current business. Additionally, her background in reproductive genetics will be beneficial as we pursue other markets where our DEPArray technology has value, such as prenatal genetic testing.”

“I am extremely excited to join Silicon Biosystems, Inc.” said Dr. Bischoff. “Silicon Biosystems’ innovative and state of the art DEPArray platform enables isolation of pure rare cell populations and I’m thrilled to be leading the team in developing strategies that will enable highly sensitive downstream molecular diagnostics."

About Silicon Biosystems
Silicon Biosystems, S.p.A., a wholly owned and operated subsidiary of The Menarini Group, manufactures and sells the DEPArray platform which is based on the principle of dielectrophoresis to isolate and manipulate cells in suspension with a microelectronic array. The approach, patented by Silicon Biosystems, offers the unique ability to control individual cells and micro-particles inside a disposable cartridge. The DEPArray platform makes it possible to find, sort, select, and separate individual cells for further analysis or culturing. For more information on Silicon Biosystems, visit http://www.siliconbiosystems.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Casie Buschmann
Silicon Biosystems
+1 800-381-4929 Ext: 9
Email >
@SiliconBio
since: 12/2010
Follow >
Silicon Biosystems
since: 05/2011
Like >
Silicon Biosystems

Follow us on
Visit website